吉西他滨联合厄洛替尼治疗晚期胰腺癌的观察

Observation of Erlotinib (Tarceva) combined with gemcitabine in advanced pancreatic adenocarcinoma

目的:观察吉西他滨(健择)联合厄洛替尼(erlotinib,Tarceva)治疗晚期胰腺癌的疗效、临床受益反应和毒性反应。方法:12例晚期胰腺癌患者,均有组织病理学或细胞学诊断及可评价的客观指标。采用健择1000mg/m2,静脉滴注,第1、8、15天,每28天重复,同时联合Tarceva口服150mg/天。结果:12例患者中,有11例可以评价疗效,其中获得CR1例、PR3例,SD3例,总有效率为36.4%,稳定率为27.3%,临床受益反应率为72.7%。主要毒性反应是皮疹、腹泻、口腔炎、白细胞减少、血红蛋白下降、恶心、呕吐和转氨酶轻度升高等。结论:吉西他滨联合厄洛替尼是治疗晚期胰腺癌患者的有效方案,副反应可以耐受。

Objective：To evaluate the efficacy, clinical benefitial response（ CBR）, and toxicity of Tarceva combined with gemcitabine in advanced pancreatic adenocarcinoma. Methods： 12 patients were enrolled in this study, with histologically or cytologiaclly confirmed advanced pancreatic adenocarcinoma, all of whom had bidimensionally measurable leisionhs. Gemcitabine was administered as 1 000mg/m^2 weekly for 3 weeks, Tarceva was administered orally 150mg/day. Results：There were 11 of the 12 patients might be evaluated for the objective response, The total response rate was 36.4% , including 1 CR, 3 PR and 3 SD patients, and CBR was 72.7%, The major side effects were rash, diarrhea,inflammation of oral cavity, myelosuppression, and gastrointestinal tract response and slight liver function damage. Conclusion：Tarceva plus gemcitabine is an effective therapy for the patients with advanced pancreatic adenocarcinoma. The efficacy and CBR improved,and the toxicities can be tolerated.